XOMA Royalty Corp, operating in the biotechnology sector, primarily focuses on acquiring potential future economics related to pre-commercial therapeutic candidates. The company has recently expanded its portfolio and is set to capitalize on the upcoming acquisition of Turnstone Biologics Corp. This strategic move is expected to enhance XOMA's asset base and provide a non-dilutive funding source to further its acquisition strategy.

XOMA Royalty Corp, a key player in the biotechnology sector, specializes in aggregating royalties by acquiring future economic rights associated with therapeutic candidates. The company's innovative approach provides non-dilutive, non-recourse funding to advance internal drug candidates or for general corporate purposes. Recently, XOMA announced its definitive merger agreement to acquire Turnstone Biologics Corp., which is expected to significantly enhance its portfolio and financial flexibility. This strategic acquisition is likely to provide XOMA with additional economic rights and potential future earnings, contributing to its growth trajectory. The company's stock has shown resilience and growth potential, making it a notable player in the investment community. Given the upcoming merger and potential catalysts in the pipeline, XOMA is well-positioned to capitalize on these developments, which could lead to significant shareholder value.